Adeno-associated virus type 2 nonstructural protein Rep78 [621 amino acids (aa) long] affects the expression of various cellular and viral genes. In this study we examined the effects of Rep78 on expression of the luciferase gene from the human cytomegalovirus immediate-early promoter in HeLa cells and on translation of RNA encoding luciferase in rabbit reticulocyte lysate. When Rep78 and luciferase were coexpressed, the luciferase activity decreased despite increased levels of luciferase mRNA in the cells. Purified Rep78 or Rep68 fused with Escherichia coli maltose binding protein suppressed translation of luciferase RNA in vitro, but Rep52/40 fusion proteins did not. A mutated Rep78, which is 520 aa long and truncated at its C-terminus, did suppress the in vitro translation, whereas a similarly truncated Rep78 of 420 aa did not. The results indicate that Rep78/68 function to suppress gene expression through translation inhibition, which requires the N-terminal region contained within aa 1-520.
INTRODUCTION
Adeno-associated virus (AAV) type 2, a human parvovirus, is a nonenveloped small virus with a genome of 4.7 kb of single-stranded linear DNA. Propagation of AAV relies on the presence of a helper virus such as adenovirus, herpes simplex virus, and human cytomegalovirus. Without a helper virus, AAV integrates into the host genome, preferentially in a region on the q arm of human chromosome 19, and is maintained as a latent provirus . When AAV and a helper virus are coinfected to cell culture, AAV can propagate with suppression of helper virus propagation (Carter et al., 1979; Heilbronn et al., 1990) . The unique life cycle of AAV is regulated through the functions of viral nonstructural Rep proteins.
The AAV rep gene is transcribed from two promoters and encodes four overlapping multifunctional proteins, Rep78, 68, 52, and 40 (Mendelson et al., 1986) (Fig. 1) . Both Rep78 and Rep68 transcripts are initiated from the promoter at map unit 5 (P5), and the first 529 amino acids of Rep78 and Rep68 are identical (Srivastava et al., 1983) . These proteins that have ATP-dependent DNA/DNA and DNA/RNA helicase activities (Im and Muzyczka, 1990; Wonderling et al., 1995; Zhou et al., 1999) , a site-specific endonuclease (Im and Muzyczka, 1990; Snyder et al., 1990) , and the ability to bind to specific sites within the AAV terminal hairpin DNA (McCarty et al., 1994; Chiorini et al., 1994) are required for AAV DNA replication (Hermonat et al., 1984; Tratschin et al., 1984) and for integration of the AAV genome into host cell DNA (Weitzman et al., 1994; Linden et al., 1996) . Rep52 and Rep40 are transcribed from the promoter at map unit 19 (P19) (Srivastava et al., 1983) , and these proteins are required for the accumulation of single-stranded progeny genomes for encapsidation (Chejanovsky and Carter, 1989; Wistuba et al., 1995; Prasad and Trempe, 1995) .
AAV Rep proteins regulate the expression of AAV genes and affect expression from a variety of heterologous promoters. Rep78/68 down-regulate gene expression from the P5 and the P19, whereas in the presence of helper adenovirus these proteins stimulate expression from the P19 and the promoter at map unit 40 (P40, promoter for genes encoding capsid proteins) (Labow et al., 1986; McCarty et al., 1991; Pereira et al., 1997) . In 293 cells, a human cell line transformed with adenovirus, Rep proteins stimulate transcription of the reporter gene from the P40 with reduced activity of the reporter enzyme (Trempe and Carter, 1988) . Rep78/68 also have the capacity to affect gene expression from human promoters for c-myc, c-fos, c-H-ras, the human immunodeficiency virus-1 long terminal repeats (HIV-LTR), and the human papillomavirus type 18 long control region (HPV-18 LCR) (Antoni et al., 1991; Batchu and Hermonat, 1995; Hermonat, 1991 Hermonat, , 1994 Oelze et al., 1994; Horer et al., 1995) . Although these studies suggest that Rep78/68 repress transcription from heterologous promoters, a recent study shows that Rep68 increases mRNA levels transcribed from the human cytomegalovirus immediate-early promoter (CMV-IE) (Wonderling et al., 1997) . How Rep proteins regulate gene expression from heterologous promoters is yet to be elucidated.
In this study, we examined the effect of Rep78 on the transcription of the renilla luciferase gene from CMV-IE in HeLa cells transfected with plasmids expressing renilla luciferase and Rep78. Rep78 induced the increase of mRNA levels as reported for Rep68 previously (Wonderling et al., 1997) but repressed the luciferase activity, indicating that suppression of gene expression by Rep78 occurred posttranscriptionally. More directly, the addition of Rep78/68, but not Rep52/40, to the in vitro translation system inhibited translation from RNA encoding firefly luciferase. Analysis of the truncation mutants of Rep78 indicated that the N-terminal region required for the suppressive function is within amino acids 1 to 520.
RESULTS AND DISCUSSION

Suppression of gene expression from heterologous promoters by Rep78
The effects of Rep78 and Rep52 on expression of reporter genes under the control of three viral promoters, CMV-IE, HPV16-LCR, and adenovirus type 2 major late promoter (Ad2ml) were examined. CMV, HPV, and Ad2 can be helper viruses for AAV propagation and these promoters do not contain Rep-binding sequences. HeLa cells (4 ϫ 10 5 ) were transfected with a mixture of plasmids consisting of 0.02 g of one of the expression plasmids for reporter genes [the plasmid for the renilla luciferase gene driven by CMV-IE (pRL-CMV), by HPV16-LCR (pLCR-RL), and by Ad2ml (pAd2ml-RL) and the plasmid for the ␤-galactosidase (␤-gal) gene driven by CMV-IE (pCMV-␤)] and 0, 0.02, 0.06, and 0.2 g of CMV-IE-driven expression plasmid for Rep78 (pCMV78) or Rep52 (pCMV52). Expression of Rep78 and Rep52 in HeLa cells transfected with pCMV78 and pCMV52, respectively, was confirmed by immunoblotting analysis using anti-Rep antibody (anti-AAV Rep protein mouse monoclonal antibody, Clone 226.7, Progen Biotechnik GmbH, Heidelberg, Germany) (data not shown). Activities of renilla luciferase were measured at 30 h after transfection and ␤-gal activity was measured at 48 h (Fig. 2) . The data clearly show that, whereas Rep52 did not suppress expression, Rep78 suppressed expression of the reporter genes from these viral promoters used in a dose-dependent manner. The N-terminal region specific for Rep78/68 (aa 1 to 225), the central region common to all four Reps (aa 225 to 529), the major intron of AAV type 2, and the C-terminal amino acids specific for Rep68/40 are presented. The mutants differentially truncated at their C-terminus are used in this study (bottom three rows). Rep78 370 , Rep78 440 , and Rep78 520 are composed of aa 1 to 370, aa 1 to 440, and aa 1 to 520 of Rep78, respectively.
FIG. 2.
Effect of Rep78 (A) and Rep52 (B) on expression of renilla luciferase from cytomegalovirus immediate-early promoter (pRL-CMV), from human papillomavirus type 16 long control region (pLCR-RL), and from adenovirus type 2 major late promoter (pAd2ml-RL) and ␤-galactosidase from cytomegalovirus immediate-early promoter (pCMV-␤). Luciferase or ␤-galactosidase activity of lysate of HeLa cells transfected with a mixture of a Rep plasmid and an expression plasmid for Rep protein at different ratios was measured and enzyme activities from cells transfected with a Rep plasmid relative to those obtained without a Rep plasmid were calculated. Data obtained from four independent transfections are presented with standard deviations (bars).
Effects of Rep78 on transcription of the luciferase gene from the CMV-IE promoter
To analyze the effect of Rep78 on transcription from CMV-IE, the levels of transcripts from pRL-CMV in the presence of Rep78 were measured by real-time PCR with an ABI PRISM 7700 (PE Applied Biosystems, Foster City, CA) (Fink et al., 1998) . Three sets of HeLa cell cultures were transfected with a mixture of pRL-CMV and pCMV78 (or pCMV␤) at a ratio of 1 to 10, and total DNA, total mRNA, and cell lysate were prepared from each culture set at 24, 30, and 48 h after transfection. pRL-CMV in total DNA and mRNA transcribed from pRL-CMV in total mRNA were quantified and renilla luciferase activities in the lysate were measured. Since Rep78 might affect its own expression in a feedback loop, we attempted to analyze the earliest events induced by Rep78. Levels of luciferase mRNA were normalized to levels of pRL-CMV and levels of mRNA in HeLa cells with Rep78 relative to those without Rep78 are shown in Fig.  3A . At 24 and 30 h the mRNA was more abundant in the cells containing Rep78 than in those containing ␤-gal, indicating that Rep78 increased mRNA levels transcribed from CMV-IE as reported previously (Wonderling et al., 1997) . However, luciferase activity in the lysate of cells containing Rep78 was comparable to that in the lysate containing ␤-gal at 24 h (Fig. 3B ) and was lower than those expected from the levels of mRNA (Fig. 3A) . The data strongly suggest that posttranscriptional steps for the luciferase gene expression are blocked by Rep78.
Suppression of translation in vitro by Rep proteins
Suppression of translation by Rep proteins was examined with an in vitro translation system composed of rabbit reticulocyte lysate and commercially purchased firefly luciferase RNA (Promega Co. Ltd.). Four Rep proteins, maltose binding protein (MBP)-Rep78, MBPRep68, MBP-Rep52, and MBP-Rep40, were bacterially expressed as fusion proteins with MBP, purified by affinity column chromatography (Fig. 4A) , and added to the translation system to test their function.
Addition of MBP-Rep78 to the reaction mixture resulted in the dose-dependent suppression of luciferase activity (Fig. 4B) . Since luciferase activity produced in the system was not affected by adding MBP-Rep78 to the mixture after translation reaction ceased (data not shown), it was not the luciferase assay system on which Rep78 exerted its effect.
Suppressive effects of the other three Rep proteins, Rep68, Rep52, and Rep40, on the translation reaction in the in vitro system were tested (Fig. 4C) . Rep68 suppressed translation as effectively as Rep78, but Rep52 and Rep40 did not. Thus, the suppressive activity for translation was common to the "large" Rep proteins but not shared by the "small" Rep proteins, indicating that the N-terminal region of Rep78/68 not present in Rep52/40 was necessary for translational suppression. The results were concordant with those of cotransfection assays, indicating that, whereas Rep52 did not, Rep78 suppressed the expression of reporter genes in the cells (Fig. 2) .
Three truncation mutants of Rep78, Rep78 371 , Rep78 440 , and Rep78 520 (Fig. 1) , were constructed and examined for their suppressive effect on translation (Fig. 4C) . Rep78 520 , which has a stop codon at amino acid 521, retained the suppressive activity but the other two truncation mutants had lost it. Therefore, the C-terminal 101-aa region of Rep78 was not necessary but the stretch from aa 1 to 520 was indicated to contain some functional region(s) necessary for the translational suppression.
In summary, this study has shown that AAV Rep78 increases the level of mRNA transcribed from CMV-IE in cells soon after transfection and that Rep78/68 repress translation of RNA in vitro. The data are consistent with the previous findings that Rep proteins increase the level of chloramphenicol acetyltransferase mRNA transcribed from the P40 while apparently suppressing the enzyme activity in 293 cells (Trempe and Carter, 1988) . A part of the Rep proteins are detectable in the cytoplasm (Im and Muzyczka, 1990) , although the proteins localize mainly in the nuclei (Mendelson et al., 1986; Trempe et al., 1987) . It is, therefore, very likely that Rep78/68 inhibit expression of proteins directed under the control of CMV-IE through suppression of translation.
The significance of the translational suppression by Rep proteins in relation to the life cycle of AAV is unclear at present. It is conceivable, however, that the function of Rep proteins to affect gene expression from heterologous viral promoters may contribute, at least partly, to maximum utilization of cellular resources for propagation of AAV in a cell coinfected with a helper virus. If this is the case, it is important to know the mechanisms that allow the protein synthesis directed by AAV to escape from the translational suppression.
AAV is one of the most promising gene therapy vectors, with its stability, low antigenicity, apparent lack of pathogenicity, and ability to integrate into the unique region of chromosome 19 (AAVS1). Since the integration of AAV into AAVS1 seems not to be pathogenic to humans, AAVS1 may be an ideal region for insertion of the vector. However, the rep gene has been deleted from the recombinant AAV vectors used in clinical trials so far (Flotte et al., 1993) , because the pivotal Rep proteins are thought to be potentially cytotoxic (Hermanns et al., 1997; Kube et al., 1997) . To give AAV vectors the capability of introducing therapeutic genes into AAVS1, the properties of Rep proteins should be dissected thoroughly and, if possible, functions not necessary for the site-specific integration should be removed. For that purpose, extensive studies of the structure and function of Rep proteins are required.
MATERIALS AND METHODS
Plasmids
The expression plasmid for renilla luciferase from human CMV-IE (pRL-CMV) was purchased from Promega Corp. gene. pCMV78 was constructed by replacement of the ␤-gal gene of pCMV-␤ with the rep78 gene (from nt 321 to 2186 of AAV2; GenBank Accession No. AF043303). To allow pCMV78 to express Rep78 protein alone the following modifications of rep gene were made by PCRbased mutagenesis: (i) to destroy the P19 TATA box, TATTTAA from nt 843 to 849 was changed to TACCTGA; (ii) to destroy the P40 TATA box, TATAA from nt 1823 to 1827 was changed to CATCA; (iii) to destroy P40, TCA from nt 1851 to 1853 was changed to AGC; (iv) to destroy the splice donor site, CAGG from nt at 1904 to 1907 was changed to TCGA; and (v) to destroy the splice acceptor site, GAT from nt 2227 to 2229 was changed to CAA. pCMV52, the expression plasmid for Rep52, was constructed by removal of the region from nt 321 to 992. Structures of newly constructed plasmids were verified by nucleotide sequencing with an ABI Prism 310 autosequencer (PE Applied Biosystems).
Fusion proteins
Rep proteins fused with MBP were expressed using bacterial expression plasmid pMAL-c2 (New England BioLabs, Inc., Beverly, MA). A DNA fragment encoding Rep78 was isolated from pCMV78 and inserted into pMALc2 to generate pMAL-Rep78. pMAL-Rep68 and pMAL-Rep52 were constructed by removal of the regions from nt 1907 to 2227 and nt 321 to 992 from pMAL-Rep78, respectively. pMAL-Rep40 was constructed by removal of the region from nt 321 to 992 from pMAL-Rep68. Truncation mutants of Rep78 were constructed by oligonucleotide-directed mutagenesis using the Mutan Super Express Km Kit (TaKaRa Co. Ltd., Kyoto, Japan). pMAL-Rep78 371 , pMAL-Rep78 440 , and pMALRep78 520 have stop codons at aa 372, 441, and 521, respectively.
MBP-Rep proteins produced in Escherichia coli JM109 transformed with each of the pMAL-Rep plasmids were extracted by brief sonication, and then the extracted proteins were purified by affinity column chromatography according to the manufacturer's protocol. The purified proteins were dialyzed against buffer [25 mM NaCl, 2.5 mM Tris-HCl (pH 7.4), 0.125 mM EDTA] and quantitated with a DC Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). MBP-Rep78 prepared in this study had DNA/ DNA helicase activity, indicating its correct folding (data not shown).
Transfection
HeLa S3 cells, cultured in Dulbecco's modified Eagle's medium supplemented with antibiotics and 10% fetal calf serum, were plated at a density of 4 ϫ 10 4 per well on 24-well plates or at 4 ϫ 10 5 per well on 6-well plates 24 h prior to transfection. For assay of luciferase or ␤-galactosidase activities, cells in 24-well plates were transfected with a mixture of plasmids consisting of 0.02 g of reporter plasmid and 0 to 0.2 g of pCMV78 or pCMV52. Total DNA for transfection was adjusted to 0.22 g per well with pCMV␤ or pCMV-C, which express a biologically inactive short peptide from CMV-IE (unpublished data), in the case where pCMV␤ was used as the reporter plasmid. For extraction of DNA or mRNA for realtime PCR, cells in 6-well plates were transfected with a mixture of 0.035 g of pRL-CMV and 0.35 g of either pCMV78 or pCMV␤. Effectene Transfection Reagent (Qiagen GmbH, Hilden, Germany) was used, following the manufacturer's instructions.
Assay of luciferase activity
Renilla and firefly luciferase activity of the lysate of HeLa cells transfected with the expression plasmids were measured with a Dual-Luciferase Reporter Assay System (Promega Corp.) with an LB96V luminometer (Berthold Co. Ltd., Wildbad, Germany). ␤-Gal activity of the cellular lysate was determined with Luminescent ␤-Galactosidase Detection Kit II (Clontech Laboratories) using the luminometer. Enzyme activities in the lysates with Rep protein relative to those without Rep protein were calculated using data obtained from three to four independent experiments. Since the normalization of the luciferase activities to the amount of luciferase plasmid DNA recovered from the lysates did not affect the results, the results without the normalization are presented.
Real-time PCR
Total DNA was isolated from cells with QIAamp (Qiagen GmbH) and digested with RNase A. mRNA was isolated with a QuickPrep Micro mRNA Purification Kit (Amersham Pharmacia Biotech, Uppsala, Sweden) and treated with RT-grade DNase I (Nippon Gene, Tokyo, Japan). For mRNA quantitation, first-strand cDNA was synthesized in a 50-l mixture [50 ng of mRNA, 1ϫ TaqMan RT buffer (PE Applied Biosystems), 5.5 mM MgCl 2 , 500 M each dNTP (dATP, dCTP, dGTP and dTTP), 2.5 M random hexamers, 20 U RNase inhibitor, and 62.5 U MultiScribe reverse transcriptase (PE Applied Biosystems)] by incubation at 25°C for 10 min, at 48°C for 30 min, and at 95°C for 5 min and then cooled to room temperature. Five microliters of the cDNA or 5 ng of total DNA was included in a 25-l PCR mixture containing 12.5 l of TaqMan universal PCR master mix (PE Applied Biosystems). For renilla luciferase plasmid and cDNA quantitation the following oligonucleotides were used (final concentration in parentheses): forward primer, 5Ј-CCTCTTCTTATTTATGGCGACATGT-3Ј (200 nM); reverse primer, 5Ј-GCCTGATTTGCCCATACCAA-3Ј (800 nM); and probe, 5Ј-FAM (6-carboxyfluorescein)-TGCCACATATT-GAGCCAGTAGCGCG-TAMRA(6-carboxytetramethylrhodamine)-3Ј (200 nM). For ␤-actin DNA and GAPDH mRNA quantitation, primers and probes of TaqMan ␤-actin control reagent and TaqMan GAPDH control reagent (PE Applied Biosystems), respectively, were used. The measurement was done in an ABI Prism 7700 sequence detector (PE Applied Biosystems) by PCR consisting of 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s, and 60°C for 1 min. Standard curves for luciferase DNA and mRNA, for ␤-actin DNA, and for GAPDH mRNA were generated using plasmid pRL-CMV, total human DNA, and cDNA synthesized from total cellular RNA, respectively, and analysis of data was done according to the manufacturer's instructions. Levels of pRL-CMV and luciferase mRNA in cells were normalized using ␤-actin DNA and GAPDH mRNA as a standard, respectively, and then levels of luciferase mRNA were normalized to levels of pRL-CMV.
In vitro translation
A reaction mixture (25 l) containing 17.5 l of the Rabbit Reticulocyte Lysate System (Promega Corp.), 0.01 g of Luciferase Control RNA (purchased from Promega Corp.), and MBP-Rep proteins was incubated at 30°C for 90 min, snap-frozen in liquid nitrogen to stop the reaction, and kept on ice. To measure firefly luciferase activity, 20 l of the sample, which was diluted at 1 to 8 using the passive lysis buffer (Promega Corp.), was used.
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